JP2008507529A5 - - Google Patents

Download PDF

Info

Publication number
JP2008507529A5
JP2008507529A5 JP2007522656A JP2007522656A JP2008507529A5 JP 2008507529 A5 JP2008507529 A5 JP 2008507529A5 JP 2007522656 A JP2007522656 A JP 2007522656A JP 2007522656 A JP2007522656 A JP 2007522656A JP 2008507529 A5 JP2008507529 A5 JP 2008507529A5
Authority
JP
Japan
Prior art keywords
composition
receptor
antibody
intended
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007522656A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008507529A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/025588 external-priority patent/WO2006014646A2/en
Publication of JP2008507529A publication Critical patent/JP2008507529A/ja
Publication of JP2008507529A5 publication Critical patent/JP2008507529A5/ja
Pending legal-status Critical Current

Links

JP2007522656A 2004-07-22 2005-07-20 抗サイトカインレセプター抗体を用いる診断のための方法 Pending JP2008507529A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59040004P 2004-07-22 2004-07-22
PCT/US2005/025588 WO2006014646A2 (en) 2004-07-22 2005-07-20 Methods for diagnosis using anti-cytokine receptor antibodies

Publications (2)

Publication Number Publication Date
JP2008507529A JP2008507529A (ja) 2008-03-13
JP2008507529A5 true JP2008507529A5 (https=) 2008-09-11

Family

ID=35787681

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007522656A Pending JP2008507529A (ja) 2004-07-22 2005-07-20 抗サイトカインレセプター抗体を用いる診断のための方法

Country Status (7)

Country Link
US (1) US7727528B2 (https=)
EP (1) EP1781818B1 (https=)
JP (1) JP2008507529A (https=)
AU (1) AU2005269820B2 (https=)
CA (1) CA2574496C (https=)
DK (1) DK1781818T3 (https=)
WO (1) WO2006014646A2 (https=)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0315656D0 (en) * 2003-07-03 2003-08-13 Oxonica Ltd Metal oxide formulations
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US8404235B2 (en) 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
HUE032563T2 (en) 2007-05-21 2017-09-28 Alderbio Holdings Llc Antibodies to IL-6 and their use
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
KR20170036814A (ko) * 2007-05-21 2017-04-03 앨더바이오 홀딩스 엘엘씨 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
US8058204B2 (en) * 2008-10-24 2011-11-15 GM Global Technology Operations LLC Method for generating a shell of noble metal overlaid on a core of non-noble metal, and catalysts made thereby
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
ES2706403T3 (es) 2008-12-10 2019-03-28 Joslin Diabetes Center Inc Métodos para diagnosticar y predecir una enfermedad renal
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
WO2011066374A2 (en) 2009-11-24 2011-06-03 Alder Biopharmaceuticals, Inc. Antagonists of il-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
US9304134B2 (en) 2010-11-23 2016-04-05 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of anemia
US20170038382A1 (en) * 2014-01-24 2017-02-09 Ntercept, Llc Methods and compositions for immune dis-inhibition
MX2017003903A (es) 2014-10-03 2017-09-15 Ntercept Llc Composiciones y metodos para inhibir la actividad biologica de biomoleculas solubles.
EA201890391A1 (ru) 2015-07-29 2018-08-31 НАНОТИКС, ЭлЭлСи Модульные композиции для утилизации растворимых биомолекул и связанные с этим способы
WO2017083525A1 (en) * 2015-11-11 2017-05-18 Opi Vi- Ip Holdco Llc Composition and methods for anti-tnfr2 antibodies
US10858422B2 (en) 2016-05-31 2020-12-08 Abcentra, Llc Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody
EP3463416A1 (en) 2016-05-31 2019-04-10 CardioVax, LLC Methods for diagnosing and treating systemic lupus erythematosus
US11065345B2 (en) 2017-01-04 2021-07-20 Nanotics, Llc Methods for assembling scavenging particles

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6096289A (en) 1992-05-06 2000-08-01 Immunomedics, Inc. Intraoperative, intravascular, and endoscopic tumor and lesion detection, biopsy and therapy
JPH0630788A (ja) * 1992-07-16 1994-02-08 Otsuka Pharmaceut Co Ltd ヒトインターロイキン−1に対する組換え抗体
US20030138426A1 (en) * 1997-10-21 2003-07-24 Human Genome Sciences, Inc. Human tumor necrosis factor receptor-like proteins TR11, TR11SV1, and TR11SV2
US6620382B1 (en) * 1998-05-22 2003-09-16 Biopheresis Technologies, Llc. Method and compositions for treatment of cancers
US20020039764A1 (en) * 1999-03-12 2002-04-04 Rosen Craig A. Nucleic, acids, proteins, and antibodies
CN1981868A (zh) * 2000-03-31 2007-06-20 拜奥根Idec公司 抗细胞因子抗体或拮抗剂与抗-cd20在b细胞淋巴瘤治疗中的联合应用
US7358041B2 (en) * 2001-11-30 2008-04-15 Short Mary K Antibodies to magmas and uses thereof
US20040072237A1 (en) * 2001-12-26 2004-04-15 Barry Schweitzer Use of cytokines secreted by dendritic cells
WO2005107802A2 (en) * 2004-04-30 2005-11-17 Biopheresis Technologies, Llc Method and system to remove soluble tnfr1, tnfr2, and il2 in patients

Similar Documents

Publication Publication Date Title
JP2008507529A5 (https=)
JP2009539841A5 (https=)
JP2009518447A5 (https=)
Brockhaus et al. Identification of two types of tumor necrosis factor receptors on human cell lines by monoclonal antibodies.
ES2270479T3 (es) Utilizacion de composiciones farmaceuticas que contienen una anticitoquina para el tratamiento de esclerosis multiple.
ES2197912T3 (es) Utilizacion de anticuerpos anti-tnf en la preparacion de medicamentos para tratar enfermedades con porcentaje serico elevado de interleucina-6.
Rogers et al. Myelopathy in Sjögren’s syndrome: role of nonsteroidal immunosuppressants
JP2019178142A5 (https=)
Machold et al. Adalimumab–a new TNF-α antibody for treatment of inflammatory joint disease
JP2025061126A (ja) Ror1抗体イムノコンジュゲートによる癌の治療
JP2009518441A5 (https=)
O'Brien et al. Evaluation of merocyanine 540-sensitized photoirradiation as a means to inactivate enveloped viruses in blood products
RU2014105496A (ru) Способы снижения числа эозинофилов
RU2007129033A (ru) Моноклональные антитела против nkg2a
JP2006528626A5 (https=)
JP2010509234A5 (https=)
JP2014533279A5 (https=)
JP2019501206A5 (https=)
JP2009537563A5 (https=)
Bresnihan The prospect of treating rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist
IL313915A (en) Methods for treating muscle-invasive urinary tract cancer or muscle-invasive bladder cancer with antibody-drug conjugates (ADC) that bind to 191P4D12 proteins
JP2006528627A5 (https=)
RU2008102911A (ru) Фармацевтические составы на основе гуанфацина, подходящие для ежедневного введения в виде единичной дозированной формы
SK287522B6 (sk) Použitie inhibítorov produkcie a/alebo účinku IL-18
Kreuter et al. Intravenous immunoglobulin for recalcitrant subacute cutaneous lupus erythematosus